News Release

Apixaban to prevent recurrence after cryptogenic stroke in patients with atrial cardiopathy

JAMA

Peer-Reviewed Publication

JAMA Network

About The Study: In patients with cryptogenic stroke and evidence of atrial cardiopathy without atrial fibrillation, oral anticoagulant therapy with apixaban did not significantly reduce recurrent stroke risk compared with aspirin in this randomized clinical trial that included 1,015 participants. 

Authors: Hooman Kamel, M.D., of Weill Cornell Medicine in New York, is the corresponding author.

To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/

(doi:10.1001/jama.2023.27188)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

Media advisory: This study is being released to coincide with presentation at the International Stroke Conference 2024.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2023.27188?guestAccessKey=8dbc1dfe-3156-41b0-bc51-06e41924a613&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=020724

 


Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.